Watertown, MA's Syros Pharmaceuticals has banked a massive $53 million Series B to support its innovative approach to treating cancer, targeting the genetic switches responsible for tumor growth.
The Association of Clinical Research Organizations, which represents the world's largest CROs, is putting together a sort of contractors' council to weigh in on the efforts of TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.
With the goal line for lung cancer in sight at the FDA as it races with an ambitious R&D team at Bristol-Myers Squibb, Merck has grabbed bragging rights to the agency's breakthrough drug designation for the checkpoint inhibitor pembrolizumab (Keytruda) for that golden market opportunity.
Dr. Patrick Soon-Shiong has teamed up with the University of Oxford and others to further the United Kingdom's plan to build the "NASA of biomedicine." Some of the £141 million ($227 million) investment is earmarked for establishing computing infrastructure to support the U.K.'s genomics project.
Amid the rise of antibiotic-resistant superbugs in hospital systems and facilities, scientists at Johns Hopkins are developing a real-time tracking system that could quickly diagnose and monitor antibiotic-resistant bacterial infections.
WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
In a week during which 23andMe showed results from a clutch of its research programs at the American Society of Human Genetics annual meeting, it also tasked an industry veteran with winning new partnerships.
Physical therapy to help stroke patients regain hand motor function after a stroke is so highly repetitive that patients often struggle through it. Irvine,CA-based startup Flint Rehabilitation Devices has launched a device that could make that process more effective and less excruciating.
Eli Lilly is expanding its relationship with Canadian biotech Zymeworks, signing a broader deal that promises up to $375 million in milestones for its partner as the two collaborate on cancer immunotherapies.
Close to two years after Celgene closed its first development deal with Sutro Biopharma, the prolific partnering machine at the big biotech has come back and taken an option on buying the company and its antibody-drug conjugates and bispecifics. And Celgene is expanding their collaboration to include immuno-oncology drugs, the hottest R&D field in biotech.